Staidson Beijing Biopharma (300204) — Cash Flow Quality Index
Staidson Beijing Biopharma (300204) has a Cash Flow Quality Index of -15.09x as of June 2024. Operating cash flow of CN¥-5.23 Million is below net income of CN¥346.39K, suggesting accrual-heavy earnings not yet converted to cash. Explore Staidson Beijing Biopharma long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Staidson Beijing Biopharma Cash Flow Quality Index (2008–2019)
Historical Cash Flow Quality Index for Staidson Beijing Biopharma across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 300204 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Staidson Beijing Biopharma (2008–2019)
Year-by-year earnings quality comparison for Staidson Beijing Biopharma. For live market cap and the full company financial profile, see 300204 stock market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2019 | 1.62x | CN¥44.34 Million | CN¥27.30 Million | ▲ +31.9% |
| 2018 | 1.23x | CN¥165.08 Million | CN¥134.06 Million | ▲ +17.2% |
| 2017 | 1.05x | CN¥273.64 Million | CN¥260.34 Million | ▲ +26.0% |
| 2016 | 0.83x | CN¥212.55 Million | CN¥254.87 Million | ▼ -24.4% |
| 2015 | 1.10x | CN¥231.01 Million | CN¥209.42 Million | ▲ +4.1% |
| 2014 | 1.06x | CN¥206.85 Million | CN¥195.28 Million | ▲ +4.2% |
| 2013 | 1.02x | CN¥111.36 Million | CN¥109.57 Million | ▲ +80.6% |
| 2012 | 0.56x | CN¥90.19 Million | CN¥160.24 Million | ▼ -32.6% |
| 2011 | 0.83x | CN¥87.01 Million | CN¥104.26 Million | ▼ -24.9% |
| 2010 | 1.11x | CN¥63.91 Million | CN¥57.50 Million | ▼ -7.2% |
| 2009 | 1.20x | CN¥42.37 Million | CN¥35.36 Million | ▲ +21.2% |
| 2008 | 0.99x | CN¥16.23 Million | CN¥16.42 Million | — |